Innovation in PCR

Making a difference in the world of diagnostics

Modifications to PCR methods enhanced its utility in healthcare.

The development of real-time PCR, marked a significant technological leap in terms of every-day utility. The approach allows the signal from an amplified target to be read immediately after each cycle (the process by which a target molecule is doubled), enabling analyses of smaller samples with greater accuracy.

Some of the first PCR tests targeted burdensome viruses, including human immunodeficiency virus (HIV) , cytomegalovirus (CMV) , hepatitis C virus (HCV), and hepatitis B virus (HBV), and more recently have been used to target transplant-associated infectious agents, like Epstein-Barr-Virus (EBV), BK virus (BKV)  and adenovirus (ADV).

As the use of PCR broadened into other disciplines and disease areas, the number of organisms, pathogens, or conditions that could be diagnosed with PCR expanded. Using multiplex tests, multiple targets can be detected at the same time from a single sample to form a better picture of a patient’s status.

The far-reaching impact of automation

Automation is arguably the most important development in maximizing the adoption of PCR in healthcare settings.

Minimizing manual touchpoints presents several benefits to patients, technicians, and laboratory leadership.

• Generating reliable results consistently, sample after sample

• Eliminating staff exposure to hazardous chemicals and infectious agents

• Increasing the value-add from laboratory personnel

What began as a time-consuming manual process, spread out across several different rooms with stringent control measures in place, can now be performed in a matter of minutes in an analyzer the size of a shoebox for point-of-care and emergency room settings.

Even core laboratories and established molecular labs can benefit from integrating additional automation. From sample preparation and post-analytical processing, to robust IT solutions and analytics, the ecosystem of innovation surrounding PCR is not slowing down.

From the initial investment in PCR in the early 1990’s until today, Roche has been at the forefront of progress with this powerful technology.

From assays and analytics to hardware, software, and robotics, Roche’s drive to improve the diagnostic utility of PCR is extensive. Going forward, Roche will continue to advance the potential of PCR to make real differences in the lives of patients, laboratories and healthcare professionals everywhere.